These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8212152)

  • 1. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial.
    Hings IM; Filipovich AH; Miller WJ; Blazar BL; McGlave PB; Ramsay NK; Kersey JH; Weisdorf DJ
    Transplantation; 1993 Sep; 56(3):577-80. PubMed ID: 8212152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft-versus-host disease prophylaxis with anti-T-cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone-marrow transplantation.
    Filipovich AH; Krawczak CL; Kersey JH; McGlave P; Ramsay NK; Goldman A; Goldstein G
    Br J Haematol; 1985 May; 60(1):143-52. PubMed ID: 3890926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation.
    Hings IM; Severson R; Filipovich AH; Blazar BR; Kersey JH; Ramsay NK; McGlave PB; Weisdorf DJ
    Transplantation; 1994 Aug; 58(4):437-42. PubMed ID: 8073512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy.
    Roy J; McGlave PB; Filipovich AH; Miller WJ; Blazar BR; Ramsay NK; Kersey JH; Weisdorf DJ
    Bone Marrow Transplant; 1992 Jul; 10(1):77-82. PubMed ID: 1515883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.
    Pidala J; Hamadani M; Dawson P; Martens M; Alousi AM; Jagasia M; Efebera YA; Chhabra S; Pusic I; Holtan SG; Ferrara JLM; Levine JE; Mielcarek M; Anasetti C; Antin JH; Bolaños-Meade J; Howard A; Logan BR; Leifer ES; Pritchard TS; Horowitz MM; MacMillan ML
    Blood; 2020 Jan; 135(2):97-107. PubMed ID: 31738834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease.
    Furlong T; Leisenring W; Storb R; Anasetti C; Appelbaum FR; Carpenter PA; Deeg HJ; Doney K; Kiem HP; Nash RA; Sanders JE; Witherspoon R; Thompson D; Martin PJ
    Biol Blood Marrow Transplant; 2002; 8(4):206-12. PubMed ID: 12014809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease.
    Sadeghi B; Remberger M; Gustafsson B; Winiarski J; Moretti G; Khoein B; Klingspor L; Westgren M; Mattsson J; Ringdén O
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1965-1969. PubMed ID: 31173898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
    Kumar S; Wolf RC; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2002 Aug; 30(3):161-5. PubMed ID: 12189534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. rhGM-CSF after allogeneic bone marrow transplantation from unrelated donors: a pilot study of cyclosporine and prednisone as graft-versus-host disease prophylaxis.
    Nemunaitis J; Anasetti C; Bianco JA; Hasen J; Singer JW
    Leuk Lymphoma; 1993 Jun; 10(3):177-81. PubMed ID: 8220115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Beelen DW; Quabeck K; Kaiser B; Wiefelspütz J; Scheulen ME; Graeven U; Grosse-Wilde H; Sayer HG; Schaefer UW
    Transplantation; 1990 Sep; 50(3):421-7. PubMed ID: 2402791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease.
    Iyer RV; Hahn T; Roy HN; Battiwalla M; Cooper M; Anderson B; Paplham P; Brown K; Bambach B; Segal BH; McCarthy PL
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):587-92. PubMed ID: 16041308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
    Chao NJ; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM
    N Engl J Med; 1993 Oct; 329(17):1225-30. PubMed ID: 8413388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell frequency analysis does not predict the incidence of graft-versus-host disease in HLA-matched sibling bone marrow transplantation.
    Wang XN; Taylor PR; Skinner R; Jackson GH; Proctor SJ; Hedley D; Dickinson AM
    Transplantation; 2000 Aug; 70(3):488-93. PubMed ID: 10949192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival.
    Nevo S; Enger C; Swan V; Wojno KJ; Fuller AK; Altomonte V; Braine HG; Noga SJ; Vogelsang GB
    Transplantation; 1999 Mar; 67(5):681-9. PubMed ID: 10096522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.